Issues | Information

Reports

Medicines Australia Annual Reports

A comparative analysis of the role and impact of Health Technology Assessment   5021k (May 2011)

Over the last ten years, Health Technology Assessment (HTA) has become an increasingly important part of the assessment system for new medicines. It is generally agreed that HTA has the potential to assist payers in making informed decisions about allocating resources (including expenditure on medicines) in the health system. However, it is also possible that a poorly designed or managed HTA process runs the risk of denying patients appropriate access to medical technologies, inefficiently allocating resources, constraining clinical freedom and sending distorted signals to medical technology providers.

To this end a considerable amount of effort has been put into developing best practice principles which demonstrate a degree of consensus between academia, payers and industry. Charles River Associates (“CRA”) was asked by EFPIA, PhRMA, Medicines Australia and EuropaBio to undertake a comparative assessment of the role and impact of Health Technology Assessment (HTA) in different parts of the world. In this report, we use these principles to compare how different systems use HTA, the basis of the approach they apply, how it works in practice and the consequences for the key stakeholders.

Activity Indicators for the Pharmaceutical Benefits Scheme Report  30k (September 2010)

PBS Activity – Graphs  37k

This report presents the third annual set of outcomes resulting from a collaborative project between Medicines Australia, the Department of Health and Ageing and the Pharmaceutical Benefits Advisory Committee (PBAC) to jointly develop indicators that can be used to monitor the listing processes of the Pharmaceutical Benefits Scheme (PBS).

The primary purpose of these indicators is to facilitate the identification of trends in the process of adding items to the PBS that may provide the basis for further dialogue.

The Impact of PBS Reforms on PBS Expenditure and Savings 1043k (December 2009)

This new report by the Centre for Strategic Economic Studies (CSES) at Victoria University examines the impact of PBS reform measures since their implementation. CSES was commissioned by Medicines Australia to analyse trends in overall PBS expenditure and to report on how recent reforms have affected stakeholders, namely, Government, pharmacists, wholesalers, manufacturers and patients. The report also models the potential impact of the PBS price disclosure mechanism. The findings were reviewed favourably by Access Economics.

AMWG interim report to the Minister for Health and Ageing 464k (July 2008)

A report form the joint Medicines Australia / Deprtment of Health and Ageing. The Access to Medicines Working Group.

Page updated: November 2011